"This time it is completely out of the real estate industry, there is no longer a relationship." Faced with the author's repeated confirmation, the former real estate magnate Dai Zhikang gave a very positive answer. For the Zendai Group, the past year of 2015 is destined to be written into the history of the company. In this year, Dai Zhikang and his daughter Dai Mocao’s 42.03% shares of Shanghai Zendai Real Estate Co., Ltd. Sold, officially announced the withdrawal of the real estate industry. A year later, Dai Zhikang announced in his high-profile "Himalayan Center" that he would enter the culture and health industry. The starting point of this time is Chinese medicine. Dai Zhikang's screening “In the past 20 years, the stories in the capital market have been real estate finance, or financial real estate, but in 2016, I think the story to be told in the capital market is culture and great health. And the Chinese are going to be healthy, or Starting from traditional Chinese medicine.†Dai Zhikang described the blueprint for the transformation of Zhengda: from the cultivation and processing of Chinese herbal medicines, opening medical centers, pharmacies, hospitals, and even medical education, Dai Zhikang wants to build an ecological chain related to it. . Dai Zhikang revealed that the company will deploy the health industry from scratch in the form of mergers and acquisitions. It is reported that Shanghai Jiujiantang Health Development Technology Co., Ltd. will be established as a big data platform for the Chinese medicine industry serving the whole industry chain. Han Fengli, the person in charge of the platform, said that Jiujiantang will be located in the fields of Chinese medicine, Chinese herbal medicine, Chinese medicine research institutes and even schools. According to Han Fengli, the company's existing resources include a Chinese medicine factory in Shandong. The current annual sales is 350 million yuan. At the same time, the company is acquiring a Chinese herbal medicine piece factory. If all goes well, it is expected that the total sales of the two companies will exceed 10 in 2016. 100 million yuan. But Dai Zhikang said that his goal is to build a healthy enterprise with a market value of 100 billion dollars. Obviously, one billion sales are not enough. "It is more difficult to accomplish this goal. It is necessary to know that the current market value of the largest pharmaceutical company in China, Hengrui Medicine, has reached a market value of 100 billion yuan. Compared with Kangmei Pharmaceutical, a listed company with a large volume in the Chinese medicine industry, the total market value It is only 60 billion. It is as difficult as building a successful company with a market value of 100 billion US dollars to recreate a Chinese medicine and a medicine.†Wang Hailu, a partner of Gao Tejia Investment Group, told the author. China Extract Powder For Use As Dietary Supplement Extract Powder, Extract Powder Manufacturer Shaanxi Kang New Pharmaceutical co., Ltd. , https://www.bio-pharmacies.com
